Aarti Pharma
Aarti Pharma Q1 FY27 Results & Concall Highlights: Revenue, Margins & Order Book
Q1 FY27 earnings call: what management guided on revenue, margins and order book.
What the Q1 FY27 call signalled
3 of 4 strong
Not discussed on this call: fundraise.
The short version
API segment targeted to achieve INR1,000 crores plus revenue with current and ongoing debottlenecking in steroid and anticancer blocks and new Block 5 line. Aarti Pharmalabs targets significant growth across all three segments (Xanthine derivatives, API & Intermediates, CDMO/CMO), each aiming to surpass INR1,000 crores revenue.
From Aarti Pharma's Q1 FY27 earnings-call transcript · updated 25 Aug 2026.
Revenue & Sales Performance
- API segment targeted to achieve INR1,000 crores plus revenue with current and ongoing debottlenecking in steroid and anticancer blocks and new Block 5 line.
- Xanthine derivatives expect revenue between INR900 crores to INR1,100 crores this year, with volume ramp-up from 6,000 to 9,500 tonnes in the next couple of years.
- CDMO/CMO segment aims for 40-50% growth this year, targeting to exceed 25-30% of overall company sales with 57 active projects (37 commercial).
- Overall company targeting all three segments (Xanthine, API, CDMO) to grow beyond INR1,000 crores each.
- New product launches in anticancer and antidiabetic drugs expected to contribute to growth.
- Pricing pressures acknowledged but mitigated via process intensification and cost optimization.
- Global market share target for Xanthine is 20-25% within 2 years.
Profitability & Margins
See what Aarti Pharma said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- Completed debottlenecking of steroid block at Unit 4, Tarapur, increasing capacity by 33%.
- Incremental capacity for Xanthine derivatives commercialized at end of Q1 FY '27; ramp-up expected over next quarters aiming for 80%+ utilization by FY '28.
- Both phases of Atali Block 1 (440 kL reactor capacity) becoming fully operational in Q2 FY '27, focusing on CDMO/CMO intermediate manufacturing.
- Announced INR 149 crores capex for Block 2 at Atali with 400+ kL reactor capacity; groundbreaking expected in Q3 FY '27 with 12–15 months completion.
- Block 2 dedicated to specific CDMO projects; more cost-effective than multipurpose block and a key step toward INR 1,000 crores CDMO/CMO revenue goal.
- No additional capex required for API business to achieve INR 1,000 crores revenue post debottlenecking and expansions.
- Civil work planned to support future capacity ramp-up by 200 kL at Vapi site within 6–9 months.
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Aarti Pharma said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
- The company is working with 22 customers in the CDMO/CMO segment.
- There are currently 57 active projects, with 37 in commercial stages and 20 in developmental stages.
- The CDMO segment is expected to achieve 40-50% growth this year.
- Visibility exists for multiple dedicated CDMO projects, with 3-4 projects planned for a new dedicated block.
- The company is confident of reaching INR 1,000 crores revenue in the CDMO/CMO segment.
- Additionally, the steroid and anticancer API blocks have undergone or are undergoing debottlenecking to enhance capacity.
- Combined capacity expansions, including Block 5 for steroids and ongoing anticancer expansions, position the company to achieve over INR 1,000 crores in API revenue without additional capex.
Aarti Pharma — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest: revenue ₹583 Cr, net profit ₹61 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Aarti Pharmalabs Ltd's management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- Novartis India Ltd (Q1 FY27)
Focused growth in six core therapy areas: cardiology, pain management, women's health, CNS, transplant, and ophthalmology, which contribute 40-50% of…
- IOL Chemicals & Pharmaceuticals Ltd (Q1 FY27)
Expansion plans supported by capex of INR 200-250 crores annually, with 60% towards expansion/new products and 40% towards efficiency improvements. Key concall…
- Innova Captab Ltd (Q1 FY27)
The company is confident of achieving 20%+ volume growth backed by steady ramp-up in Jammu and existing facilities. Key concall takeaways from Innova Captab…
- Glenmark Pharmaceuticals Ltd (Q1 FY27)
Chronic respiratory segment in India showing over 25% growth; oncology and cardiovascular segments also strong. Key concall takeaways from Glenmark…
Frequently Asked Questions
What were Aarti Pharma Q1 FY27 results?
API segment targeted to achieve INR1,000 crores plus revenue with current and ongoing debottlenecking in steroid and anticancer blocks and new Block 5 line. Aarti Pharmalabs targets significant growth across all three segments (Xanthine derivatives, API & Intermediates, CDMO/CMO), each aiming to surpass INR1,000 crores revenue.
What is Aarti Pharma share price analysis?
Aarti Pharma currently shows a moderate growth signal based on ranking data. The stock trades at a P/E of 34.4 with a market cap of ₹7,407 Cr. Investors should review the full earnings analysis for detailed insights.
Is Aarti Pharma planning capital expenditure?
Completed debottlenecking of steroid block at Unit 4, Tarapur, increasing capacity by 33%.
Keep Aarti Pharma on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and concall transcripts. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.